SLC27A6: A Long-chain Fatty Acid Transport Protein as a Drug Target and Biomarker

Target Name: SLC27A6

NCBI ID: G28965

SLC27A6

SLC27A6: A Long-chain Fatty Acid Transport Protein as a Drug Target and Biomarker

Introduction

Sodium channels are the most abundant ion channels in the human body, and they play a crucial role in various physiological processes, including muscle contractions, nerve impulses, and brain function. The sodium channels are also known as Na+ channels, and they are expressed in different tissues and cells throughout the body. Long-chain fatty acids (LCFAs) are an essential type of fatty acid that play a vital role in various physiological processes, including energy metabolism and brain development. However, LCFAs have been shown to be involved in various diseases, including obesity, diabetes, and cardiovascular diseases.

SLC27A6 is a protein that belongs to the SLC (sodium-dependent carotidine) gene family. It is a member of the Tmem1 superfamily and has been shown to be involved in the transport of LCFAs across the membrane of various tissues and cells. SLC27A6 is expressed in various tissues, including brain, heart, and muscle, and has been shown to play a crucial role in the transport of LCFAs across the membrane of these tissues.

SLC27A6 as a Drug Target

SLC27A6 has been identified as a potential drug target due to its involvement in various diseases. Obesity, diabetes, and cardiovascular diseases are some of the most common diseases associated with LCFAs. These diseases are caused by an imbalance of LCFAs, leading to an increased risk of complications.

SLC27A6 has been shown to be involved in the regulation of LCFAs in the brain, which is crucial for memory and cognitive function. SLC27A6 has been shown to play a role in the transport of LCFAs across the blood-brain barrier, which is a barrier that separates the brain from the blood. This is important for the delivery of essential nutrients, including LCFAs, to the brain.

SLC27A6 has also been shown to be involved in the regulation of LCFAs in muscle, which is crucial for muscle growth and maintenance. LCFAs are essential for muscle growth and repair, and muscle fibers require LCFAs to grow and function properly. SLC27A6 has been shown to play a role in the transport of LCFAs across the membrane of muscle fibers, which is important for muscle growth and maintenance.

SLC27A6 has also been shown to be involved in the regulation of LCFAs in heart, which is crucial for maintaining proper heart function. LCFAs are essential for maintaining normal heart rhythm and contractions. SLC27A6 has been shown to play a role in the transport of LCFAs across the membrane of heart muscle cells, which is important for maintaining normal heart rhythm and contractions.

SLC27A6 as a Biomarker

SLC27A6 has also been shown to be a potential biomarker for various diseases associated with LCFAs. Obesity, diabetes, and cardiovascular diseases are some of the most common diseases associated with LCFAs. These diseases are caused by an imbalance of LCFAs, leading to an increased risk of complications.

SLC27A6 has been shown to be involved in the regulation of LCFAs in obesity, which is a disease caused by an imbalance of LCFAs. Obesity is associated with various health problems, including cardiovascular diseases, diabetes, and certain cancers. SLC27A6 has been shown to play a role in the regulation of LCFAs in obesity, which is important for the development and progression of this disease.

SLC27A6 has also been shown to be involved in the regulation of LCFAs in diabetes, which is a disease caused by an

Protein Name: Solute Carrier Family 27 Member 6

Functions: Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport at the plasma membrane (PubMed:12556534). Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates (By similarity). Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation such as the heart (PubMed:12556534)

The "SLC27A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC27A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets